Evogene (EVGN)
(Delayed Data from NSDQ)
$3.13 USD
+0.06 (1.95%)
Updated Oct 1, 2024 03:59 PM ET
After-Market: $3.14 +0.01 (0.32%) 7:58 PM ET
NA Value
NA Growth NA Momentum NA VGMFundamental Charts
About PEG Ratio (TTM)
The company's trailing twelve month (TTM) PEG ratio is the P/E ratio divided by its long-term growth rate consensus. This ratio essentially compares the P/E to its growth rate, thus, for many, telling a more complete story than just the P/E ratio alone. Conventional wisdom says that a PEG ratio of 1 or less is considered good (at par or undervalued to its growth rate). A value greater than 1, in general, is not as good (overvalued to its growth rate). For example, a company with a P/E ratio of 25 and a growth rate of 20% would have a PEG ratio of 1.25 (25 / 20 = 1.25). A company with a P/E ratio of 40 and a growth rate of 50% would have a PEG ratio of 0.80 (40 / 50 = 0.80). Traditionally, investors would look at the stock with the lower P/E and deem it a bargain. But when compared to its growth rate, it doesn't have the earnings growth to justify its P/E. In this example, the one with the P/E of 40 is the better bargain because it is selling at a discount to its growth rate. So the PEG ratio tells you what you're paying for each unit of earnings growth.
EVGN 3.13 +0.06(1.95%)
Will EVGN be a Portfolio Killer in October?
Zacks Investment Research is releasing its prediction for EVGN based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for EVGN
Evogene (EVGN) Reports Q4 Loss, Misses Revenue Estimates
Mirum Pharmaceuticals, Inc. (MIRM) Reports Q4 Loss, Tops Revenue Estimates
EVGN: What are Zacks experts saying now?
Zacks Private Portfolio Services
Fate Therapeutics (FATE) Reports Q4 Loss, Tops Revenue Estimates
Here's Why Evogene (EVGN) is a Great Momentum Stock to Buy
Is Compugen (CGEN) Outperforming Other Medical Stocks This Year?
Other News for EVGN
Lavie Bio Receives Grant from Israel Innovation Authority to Advance the Development of 'MicroFermentor', a Unique Technology that Can Change the Economics of Ag-Biologicals
Evogene receives grant from IIA to advance development of 'MicroFermentor'
Evogene files to sell 3.38M ordinary shares for holders
Evogene Announces Major Management Restructuring
Evogene Ltd. Reports Mid-Year Financial Dip